[Pharmacokinetic and therapeutic monitoring in the development of theophylline-retard preparations].
After oral application of a sustained release preparation of aminophylline (2 tabl. of 350 mg b. i. d., i. e. a total doses of 1400 mg) the doses related to body mass and the average individual concentration of theophylline in serum are varying about 50% and more of the mean. The mean individual concentration in serum changes proportionally to the doses related to body mass. Furthermore two groups of patients with different theophylline concentrations can be distinguished. The reason is probably a different biotransformation. The mean concentration of theophylline in serum rises to a maximum at the 5th d. From the 8th to the 29th d of treatment the range of concentration is nearly constant. Reaching the steady state is probably overlapped by processes of enzyme induction. In about 60% of the patients the concentrations of theophylline are in the therapeutical range. When adaptation of doses to body mass takes place a higher portion can be expected. To achieve all therapeutical possibilities it is necessary to correct the doses also for the different types of biotransformation.
D001711:Biotransformation; D003692:Delayed-Action Preparations; D006801:Humans; D007700:Kinetics; D013806:Theophylline / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*
D003692:Delayed-Action Preparations; D013806:Theophylline
Pharmakokinetik und Therapieüberwachung im Rahmen der Entwicklung von Theophyllin-Retard-Präparaten.